THCV
Δ9-tetrahydrocannabivarin
Viewing r1 — May 11, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
THCV (tetrahydrocannabivarin) is a naturally-occurring cannabinoid of the phytocannabinoid class. It is the propyl homolog of Δ9-THC — the same core structure with a shorter side chain. Rather than activating cannabinoid receptors like THC does, THCV blocks them at typical doses, producing its effects by opposing endocannabinoid signaling.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
THCV was first isolated in 1970 from a cannabis tincture by Gill and colleagues in the UK.[2] GW Pharmaceuticals later advanced it into Phase 2 clinical trials for type 2 diabetes, producing the only published randomized controlled trial in humans.[3] No Phase 3 trials have followed, and THCV now circulates primarily as a minor constituent of cannabis products and in isolated supplement form.
Subjective effects include appetite suppression, increased mental clarity, and an absence of THC-like euphoria or intoxication. At clinical doses the experience is defined by what it removes — the hunger, sedation, and mental fog that THC produces are absent, replaced by a neutral, clear-headed state. At higher doses, THC-like psychoactivity could theoretically emerge, but this range has not been characterized in humans.
THCV shows no abuse liability at clinical doses and no established lethal dose in any species.[4] The primary risk is dose-dependent: at higher concentrations, THCV may switch from blocking cannabinoid receptors to partially activating them — but the threshold for this switch in humans is unknown.[1] Evidence is limited to a single 13-week clinical trial and scattered preclinical work[3] — high-dose behavior in humans is genuinely uncertain.
History[edit]
Discovery
THCV was first isolated in 1970 from a cannabis tincture derived from Pakistani-grown Cannabis sativa by Gill and colleagues in the UK.[2] Merkus formally named it tetrahydrocannabivarin in 1971, establishing the "varin" suffix for propyl-chain cannabinoids.[2] For three decades it attracted almost no pharmacological attention, eclipsed entirely by THC and CBD.
Pharmacological characterization
Thomas et al. published the first quantified receptor binding data in 2005.[5] Pertwee's 2007 review in the British Journal of Pharmacology[1] established THCV as a pharmacologically distinct cannabinoid worth investigating on its own terms.
Clinical development
GW Pharmaceuticals ran a 13-week Phase 2 trial in 62 diabetes patients under the code GWP42004, published by Jadoon et al. in 2016.[3] Jazz Pharmaceuticals acquired GW in 2021; no Phase 3 trials have been initiated. Smith (2025) published early Phase 1 data on a THCV mucoadhesive strip formulation for metabolic syndrome.[6]
The "varin" suffix denotes membership in the propyl homolog cannabinoid series — a naming convention Merkus established in 1971 that also applies to cannabidivarin (CBDV) and cannabigerovarin (CBGV). THCV is most concentrated in narrow-leaf cannabis varieties from South Africa, Afghanistan, and Pakistan. It has attracted consumer attention as "diet weed" for its appetite-suppressing properties, though clinical evidence for weight loss is absent.
Chemistry[edit]
Structural class
THCV is a phytocannabinoid — a terpenophenolic compound produced by Cannabis sativa — and the propyl homologue of Δ9-THC.[1] Where THC carries a five-carbon side chain, THCV carries three — that two-carbon difference is responsible for THCV's opposing receptor behavior. Other propyl-series cannabinoids (CBDV, CBGV) share the same biosynthetic origin from a propyl precursor.[7]
Molecular identity
Its molecular formula is C₁₉H₂₆O₂ (286.4 g/mol). THCV shares the dibenzopyran ring system common to classical cannabinoids, with a phenolic hydroxyl group essential for receptor binding.[8] It is found at highest concentrations in narrow-leaf cannabis from South Africa, Afghanistan, and Pakistan,[9] produced through a propyl-specific biosynthetic pathway.[10][11]
Pharmacology[edit]
Mechanism of action
THCV's defining feature is that it blocks the CB1 cannabinoid receptor without suppressing its baseline activity — a behavior called neutral antagonism.[5][12][1] This distinguishes it from rimonabant, a withdrawn drug that actively shut down the receptor's resting state, causing depression and suicidality in clinical use.[4][13] At CB2 receptors, THCV consistently acts as a partial activator, suppressing inflammatory signals in immune cells.[1][4][14]
At higher doses, THCV switches from blocking CB1 to partially activating it, producing THC-like effects including sedation and reduced movement.[15][1] The dose at which this switch occurs in humans has not been established.
Pharmacokinetics
No controlled human pharmacokinetic study of THCV has been published.[3] The most relevant data come from a study of the closely related Δ8-THCV isomer, which found peak blood levels 3.8–5.0 hours after oral dosing.[16] Human bioavailability, half-life, and clearance remain uncharacterized.safety citation needed
Neuroscience[edit]
Where it acts
The only published human brain imaging study found that THCV quiets the default mode network — the system active during self-referential thought — while increasing activity in the executive control network.[13] This is the opposite of THC's neural signature, and may explain why THCV produces clarity rather than intoxication at clinical doses. As a CB1 blocker, THCV also disinhibits neurotransmitter release in circuits where the endocannabinoid system normally acts as a brake, which contributes to its anticonvulsant properties.[17]
Why it matters
The endocannabinoid system maintains a baseline level of activity that regulates mood, appetite, and pain. THCV appears to blunt sharp surges in this signaling — such as the appetite response triggered by food cues — without disrupting the steady background activity that keeps mood stable.[4] This is the proposed reason THCV avoids the depression seen with rimonabant.
The dose at which THCV switches from blocking to activating the CB1 receptor in humans is unknown — animal data place the threshold at approximately 5 mg/kg in mice,[15] but scaling to humans is unreliable for lipophilic brain-active compounds. The contribution of heat-sensing ion channels and serotonin receptors to THCV's brain effects has not been separated from its cannabinoid receptor activity.[18][19] Whether THCV can reduce THC intoxication in humans — as preclinical data suggest[5] — remains untested.
Subjective Effects[edit]
THCV at clinical doses is the experience of subtraction. Where Δ9-THC adds euphoria, hunger, and cognitive haze, THCV removes them by blocking the same receptor THC activates. The result is not a high but a correction: reduced appetite drive, maintained clarity, and an unremarkable baseline that most users would not identify as psychoactive.
Among cannabinoids, THCV sits at the opposite pole from THC. Its closest functional comparison is the withdrawn pharmaceutical rimonabant — with the critical difference that THCV's gentler receptor action avoids the mood disruption that ended rimonabant's clinical use.[4]
Effect Grid
At 5 mg/day oral — the only human-tested dose — THCV is non-psychoactive. No euphoria, perceptual changes, cognitive alteration, or mood shifts were reported in the 13-week Jadoon 2016 RCT. The subjective experience at this dose is defined by absence rather than presence of effects: no THC-like intoxication, no appetite stimulation, no sedation.
Physically, measurable metabolic changes occur without subjective awareness: reduced fasting plasma glucose, improved β-cell function, raised HDL-cholesterol, and reduced apolipoprotein B. Appetite suppression is documented in animal models and fMRI data but was not reported as a subjective experience by trial participants.
This dose is a therapeutic/metabolic dose, not a psychoactive one. Standard dose-tier framing — which assumes subjective effects — does not straightforwardly apply to THCV at its only characterized human dose.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Body high · Dizziness
Timeline
Pharmacological activity begins as THCV is absorbed orally. At the only clinically tested dose (5 mg/day), no subjective onset is perceived — effects are metabolic rather than experiential. Δ8-THCV Tmax is 3.
Peak plasma concentration reached approximately 4–5 hours post-dose based on Δ8-THCV PK data. At therapeutic doses, no subjective peak occurs — metabolic effects (glucose lowering, β-cell improvement) are measurable but not felt.
Residual pharmacological activity as THCV is cleared hepatically. Terminal half-life not determined in humans. Metabolic effects may persist beyond plasma clearance due to adipose tissue sequestration.
Safety[edit]
- Acute toxicity
- Negligible
- Chronic toxicity
- Negligible
- Withdrawal
- None
- Tolerance buildup
- none
- Tolerance reset
- —
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- Δ9-THC
Toxicity
No lethal dose has been established for THCV in any species.safety citation needed In the only rigorous human trial, 62 patients took 5 mg/day for 13 weeks with no serious adverse events.[3] A second study of THCV mucoadhesive strips also reported no serious adverse events.[6]
Organ toxicity
No organ toxicity studies for THCV have been published. A related compound, Δ8-THCV, was protective of the liver — not damaging — in mouse injury models, acting through anti-inflammatory mechanisms.[20]
Psychiatric safety
The central safety question for any CB1-blocking drug is psychiatric risk. Rimonabant, a similar agent, was withdrawn because it caused depression and suicidality. THCV differs in that it is a neutral antagonist — it blocks the receptor without suppressing its resting activity — and no psychiatric adverse events occurred in the clinical trial.[3][13][4]
safety citation needed At higher doses where CB1 activation emerges, THC-like adverse effects — anxiety, paranoia, cognitive impairment — could occur but have not been characterized in humans.
Psychological risks
No psychological adverse events have been reported in clinical literature at 5 mg/day oral dosing.[3] At doses sufficient to produce CB1 partial agonism, effects similar to THC — anxiety, paranoia, transient cognitive impairment — would be expected.safety citation needed THCV's serotonin receptor activity may offer some protection against psychotomimetic effects, though this has not been confirmed in humans.[21]
Tolerance & dependence
No tolerance or dependence studies exist for THCV.safety citation needed At typical doses, THCV does not activate reward circuits the way THC does, and would not be expected to produce the receptor changes underlying THC tolerance.[4] At higher doses where CB1 agonism emerges, tolerance could develop through mechanisms analogous to THC — but no data exist.
Drug interactions
No published drug interaction studies specifically for THCV exist.safety citation needed
CB1 agonist interactions
THCV may reduce the psychoactive and therapeutic effects of Δ9-THC and other CB1 activators when taken together.[5][15]
Liver enzyme interactions
THCV is expected to be processed by the same liver enzymes as THC — CYP2C9 and CYP3A4.inferred Drugs that inhibit these enzymes (certain antifungals, macrolide antibiotics, some SSRIs, grapefruit juice) could raise THCV levels; drugs that activate them (rifampicin, carbamazepine, St. John's wort) could lower them.
safety citation needed Taking THCV alongside drugs with narrow safety margins that share these enzymes — warfarin, phenytoin, certain statins — warrants caution.
Blood sugar-lowering drug interactions
THCV was used alongside metformin in the Jadoon trial with favorable results.[3] Combining it with insulin or sulfonylureas could increase the risk of dangerously low blood sugar through additive glucose-lowering effects.
Contraindications
No substance-specific contraindication data exist for THCV. The following are inferred from its pharmacological profile:
Pregnancy and lactation: No reproductive safety data exist. Contraindicated based on general cannabinoid class principles.inferred
History of psychotic illness: At low doses, THCV's serotonin receptor activity may be antipsychotic.[21] At high doses where CB1 agonism emerges, psychotomimetic risk increases. The biphasic dose-response complicates risk assessment for this population.
Liver impairment: Impaired liver function could alter THCV processing given expected CYP2C9/CYP3A4 metabolism.inferred
Concurrent use of narrow-margin CYP2C9/CYP3A4 substrates: Relative contraindication based on uncharacterized interaction potential.inferred
Harm Reduction[edit]
Forms & Identification
THCV products have entered the consumer market as isolates, tinctures, vape cartridges, and edibles — often marketed with appetite-suppression or "energizing" claims. Because THCV is a minor cannabinoid in most cannabis, labeled THCV products rely on selective extraction from high-THCV chemovars or synthetic production. Neither process is standardized across manufacturers.
Third-party certificate-of-analysis (COA) testing is the only reliable way to confirm that a THCV product contains what it claims. Products without an accessible, batch-matched COA should be treated as unverified. Cross-contamination with THC is a particular risk for users seeking non-psychoactive effects.
Guidelines
- Verify product contents through third-party COA testing before use. Confirm THCV concentration and check for THC contamination.
- Begin with low doses and increase gradually. The dose at which THCV shifts from CB1 antagonism to partial agonism in humans is unknown.
- If using THCV alongside THC-containing cannabis, be aware that THCV may alter the character of THC intoxication by blocking CB1 receptors.
- If managing blood sugar with medication, monitor glucose levels when adding THCV, as additive glucose-lowering effects are possible.
- Do not assume that "natural" or "hemp-derived" labeling guarantees non-psychoactive content — product quality varies widely.
Set & Setting
At clinical doses (5 mg/day oral), THCV is non-psychoactive and does not require the environmental precautions associated with psychoactive cannabinoids.
At higher doses where CB1 partial agonism may emerge, the experience could shift toward THC-like psychoactivity. Because the threshold for this shift is unknown, anyone experimenting above clinical dosing ranges should use a familiar, comfortable setting, avoid driving or operating machinery, and have a trusted companion available.
Aftercare & integration. At clinical doses, THCV does not produce altered states requiring formal integration. Users taking THCV for metabolic or appetite-related purposes should track effects over days to weeks, as clinical benefits emerge gradually rather than acutely.
If higher doses produce unexpected psychoactive effects, standard cannabinoid aftercare applies: adequate hydration, light nutrition, and rest. Effects should resolve within hours for inhaled administration. If anxiety or mood disturbance persists beyond 24 hours, consult a healthcare provider.
Recovery & Support
THCV does not produce physical dependence at characterized doses and lacks the reward-circuit activation associated with compulsive cannabis use. No THCV-specific recovery resources exist.
Individuals using THCV as part of broader cannabis consumption who wish to reduce or stop use can access general cannabis support resources. SAMHSA's National Helpline (1-800-662-4357) provides free, confidential referrals. Marijuana Anonymous and SMART Recovery offer peer support for cannabis-related concerns.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
No THCV-specific emergencies have been documented in the medical literature. At clinical doses, serious adverse reactions are not expected. If symptoms arise at higher doses, the most likely scenario is THC-like psychoactive distress.
Recognizing an emergency:
- Severe anxiety, panic, or paranoia that does not resolve with reassurance
- Chest pain, rapid heartbeat, or difficulty breathing
- Confusion, disorientation, or loss of consciousness
Immediate steps:
- 1. Move the person to a calm, quiet environment.
- 2. Reassure them that cannabinoid effects are temporary and will resolve.
- 3. If symptoms are severe (chest pain, breathing difficulty, loss of consciousness), call emergency services immediately.
- 4. Do not leave the person alone until symptoms have fully resolved.
What to tell the dispatcher: State the substance taken (THCV or cannabis product containing THCV), the amount and time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
Legal Status[edit]
THCV is not scheduled under the UN Convention on Psychotropic Substances (1971), leaving regulation to individual nations.[22] In most jurisdictions, legality depends on whether THCV derives from hemp or high-THC cannabis.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States (federal) | Not explicitly scheduled | Hemp-derived THCV (from plants with ≤ 0.3% Δ9-THC) is federally legal under the 2018 Agriculture Improvement Act (Farm Bill). Marijuana-derived THCV remains Schedule I as a cannabis extract. State laws vary significantly.[23] |
| United Kingdom | Class B, Schedule 1 | Illegal to possess, supply, or produce without a Home Office license. GW Pharmaceuticals conducted Phase 2 trials under regulatory authorization.[23] |
| European Union | Not explicitly scheduled | Not listed in most national controlled substance schedules beyond cannabis. Hemp-derived THCV (from plants with less than 0.2% THC) occupies uncertain legal status in most member states.[22] |
| Canada | Regulated under the Cannabis Act (2018) | Legal for medical and recreational use when purchased from licensed retailers.[22] |
| Australia | Presumed controlled | Specific scheduling not confirmed. As a cannabis-derived compound, THCV likely falls under TGA cannabis regulations.citation needed |
| International (UN) | Not scheduled | Not listed under the UN Convention on Psychotropic Substances (1971) or the Single Convention on Narcotic Drugs (1961).[22] |
Detection and drug testing
THCV is detectable in cannabis products via HPLC and gas chromatography-mass spectrometry. Whether standard urine drug screens cross-react with THCV metabolites has not been characterized.citation needed
references
- [1]
- [2]
- [3] ^abcdefghJadoon KA, Ratcliffe SH, Barrett DA, Thomas EL, Stott C, Bell JD, O'Sullivan SE, Tan GD (2016) Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study — Diabetes Care doi:10.2337/dc16-0650
- [4]
- [5] ^abcdThomas A, Stevenson LA, Wease KN, Price MR, Baillie G, Ross RA, Pertwee RG (2005) Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist — British Journal of Pharmacology PMID:16205722
- [6] ^abSmith GL (2025) Weight Loss and Therapeutic Metabolic Effects of Tetrahydrocannabivarin (THCV)-Infused Mucoadhesive Strips — Cannabis doi:10.26828/cannabis/2024/000206